37964-14-0

Basic information

• Product Name: 1h-carbazole-2-carboxylic acid, 2,3,4,9-tetrahydro-
• Synonyms: 1h-carbazole-2-carboxylic acid, 2,3,4,9-tetrahydro-;2,3,4,9-Tetrahydro-1H-carbazole-2-carboxylic acid
• CAS NO: 37964-14-0
• Molecular Formula: C13H13NO2
• Molecular Weight: 215.24782
• Mol File: 37964-14-0.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 1h-carbazole-2-carboxylic acid, 2,3,4,9-tetrahydro-(CAS DataBase Reference)
• NIST Chemistry Reference: 1h-carbazole-2-carboxylic acid, 2,3,4,9-tetrahydro-(37964-14-0)
• EPA Substance Registry System: 1h-carbazole-2-carboxylic acid, 2,3,4,9-tetrahydro-(37964-14-0)

Safety Data

• Hazardous Substances Data: 37964-14-0(Hazardous Substances Data)

Usage

Synthesis Reference(s)

Tetrahedron, 28, p. 667, 1972 DOI: 10.1016/0040-4020(72)84030-4

Upstream product

• 16205-98-4 3-oxo-cyclohexanecarboxylic acid 
• 100-63-0 phenylhydrazine 
• 636-94-2 2-hydroxyterephthalic acid 

Relevant articles and documents

TRICYCLIC CYTOPROTECTIVE COMPOUNDS

Compounds of formula (I): in which: X is a group of formula >CR1R2 or >SO2; Y is a group of formula >NH or >CR1R2; Z is a group of formula >C=O or >CH2 or a direct bond; R1 hydrogen and R2 is hydrogen, carboxy or hydroxy; or R1 and R2 together represent an oxo group, a methylenedioxy group or a hydroxyimino group; R3 is hydrogen or lower alkyl; R4 represents two hydrogen atoms, or an oxo or hydroxyimino group; R5 is hydrogen, lower alkyl or halogen; R6 is hydrogen, lower alkoxy or carboxy; R7 and R8 are each hydrogen, lower alkyl or halogen; and pharmaceutically acceptable salts and esters thereof can be used for the treatment or prophylaxis of acute or chronic neurodegenerative diseases or conditions such as Alzheimer’s Disease, Parkinson’s Disease, Huntington’s Chorea, Multiple Sclerosis or the sequelae to acute ischaemic events such as heart attack, stroke or head injury and for protection against ischaemic damage to tissues of peripheral organs.

Fused indolecarboxamides: dopamine receptor subtype specific ligands

Disclosed are compounds of the formula: STR1 or the pharmaceutically acceptable acid addition salts thereof wherein: STR2 represents an aromatic or alicyclic ring; R 1 and R 2 are the same or different and represent hydrogen, C 1 -C 6 alkyl, halogen, hydroxy, amino, cyano, nitro, trifluoromethyl, trifluoromethoxy, C 1 -C 6 alkoxy, --O 2 CR'', --NHCOR'', --COR'', --SO m R'', where R'' is C 1 -C 6 alkyl and wherein m is 0, 1 or 2; orR 1 and R 2 independently represent --CONR''R"", or --NR''R"" where R'' and R"" independently represent hydrogen or C 1 -C 6 alkyl;R 3 is hydrogen, C 1 -C 6 alkyl, or --COR''"" where R''"" is C 1 -C 6 alkyl;R 4 is hydrogen or C 1 -C 6 alkyl; andR represents an aminoalkyl group,which compounds are useful in the treatment of affective disorders such as schizophrenia, depression, Alzheimer''s disease, movement disorders such as Parkinsonism and dystonia, and other disorders which respond to dopaminergic blockade such as substance abuse and obsessive compulsive disorders. Further, compounds of this invention are useful in treating the extrapyramidal side effects associated with the use of conventional neuroleptic agents.